GIQuant
Overview
GIQuant by Motilent is a post-processing medical image analysis software designed to measure and monitor gastrointestinal function. The tool is primarily utilized by gastroenterologists and abdominal radiologists in both pediatric and adult care settings to assist in the assessment of small bowel Crohn’s disease.
The software integrates into existing clinical workflows by processing standard dynamic (cine) magnetic resonance enterography (MRE) sequences. It operates within a DICOM-compliant environment, allowing clinicians to analyze imaging data without disrupting established PACS or imaging protocols. Notable capabilities of GIQuant include:
- Objective Motility Mapping: Uses image registration and optical flow algorithms to convert subjective cine MRI sequences into a quantitative, unitless motility score.
- Parametric Visualization: Generates parametric heatmaps of the bowel wall to help identify areas of reduced peristalsis, which are often associated with active inflammation or disease progression.
- Therapeutic Monitoring: Enables objective tracking of small bowel motility changes over time, helping clinicians assess therapeutic response and support treatment decisions.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Quantifies intestinal motility from MRI scans
- Provides objective, quantitative motility scores
- Aids in diagnosis, monitoring, and treatment response assessment
- Non-invasive assessment of gut function
- Integrates into existing DICOM-compliant clinical workflows
- Supports personalized medicine approaches
- Works with standard cine MRI sequences
- Applicable retrospectively to historical MRI datasets
- Outputs parametric maps and structured reports
- CE marked (Class IIa) in addition to FDA cleared
Use Cases
- Diagnosis of digestive diseases, especially Crohn's disease
- Monitoring disease progression and activity over time
- Assessing treatment response and efficacy of therapies
- Personalized treatment planning for patients
- Clinical research and drug development studies
- Retrospective analysis and audit of patient data
What Physicians Need to Know
Physicians should integrate GIQuant's objective small bowel motility scores with other clinical data, endoscopy findings, and biomarkers for a comprehensive assessment of Crohn's disease activity and treatment response. The tool is particularly useful for monitoring therapeutic efficacy, potentially identifying non-responders earlier, and standardizing MRI interpretations across different practitioners and institutions. It can also provide valuable insights in clinical research and drug development for IBD.
GIQuant is DICOM compatible, allowing it to integrate into standard radiology workflows and be viewed in 'off the shelf' DICOM viewers. It can be deployed within hospital infrastructure or accessed via Motilent's cloud-based platform, Entrolytics, for research and data management. Motilent has also partnered with Nuance AI solutions for deployment across healthcare providers in the U.S.
Details
| Category | Gastroenterology AI, Radiology & Imaging AI |
| Pricing |
Contact for pricing
|
| Deployment | On-premise, cloud-hybrid |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated GIQuant is FDA-cleared (Class II, 510(k)) AI medical image analysis software for assessing digestive diseases, particularly Crohn's disease, by quantifying intestinal motility from MRI scans. It is cleared for use in adults and children. |
| Integrations | |
| EHR | Not specified |
| Specialties | Gastroenterology, Radiology |
What the Web Says
GIQuant is an AI-powered software solution developed by Motilent that quantifies small bowel motility from cine MRI sequences, primarily for assessing Crohn's disease activity in both adults and children. It provides an objective motility score that can be tracked over time to monitor treatment response and disease progression, offering an additional layer of data to subjective MRI reports. The software is FDA cleared (Class II) and CE marked (Class IIa).
Overall: PositiveStrengths
- Provides objective and quantitative assessment of small bowel motility, reducing variability from subjective image interpretation.
- Helps monitor treatment response and disease progression in Crohn's disease, with motility changes potentially appearing before visible structural changes.
- Can be easily applied to standard MRE protocols and is DICOM compatible, integrating into existing hospital infrastructure.
- Aids in communicating treatment response in multidisciplinary team (MDT) meetings and provides a digestible format for patients to understand their disease control.
- Supported by multiple peer-reviewed studies and has shown to help less experienced radiologists become more consistent.
- Can be used in clinical research and drug development to support consistent assessment of Crohn's disease activity across sites.
Limitations
- The source code for the software is not open, as it is only available for commercial use.
- While GIQuant scores can change clinical impressions, there were no reported changes in actual treatment plans before and after reviewing the scores in one study.
- The learning curve for the software can be high, especially for space managers (though this con was mentioned in a review for a different product named 'Quant' on Capterra, not specifically GIQuant).
- Some general concerns about the accuracy and utility of gut microbiome tests were found on Reddit, though these were not specific to GIQuant which focuses on motility from MRI.
Based on reviews from: Motilent (motilent.com), Health AI Register, AuntMinnie, DigitalHealth.London, Oxford Academic, PMC, Reddit
Last updated: 2026-07-21
Ratings & Reviews
No reviews yet. Be the first to review this tool!
